(Q51033882)

27 March 2018

title

Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine. (English)

1 reference

27 March 2018

metastatic renal cell carcinoma

main subject

phase I clinical trial

0 references

1 reference

1 reference

1 reference

Lorenzo Cohen

1

1 reference

27 March 2018

Carl de Moor

series ordinal

2

1 reference

27 March 2018

Patricia A Parker

series ordinal

3

1 reference

27 March 2018

Robert J Amato

series ordinal

4

1 reference

27 March 2018

publication date

1 May 2002

1 reference

27 March 2018

published in

Urologic Oncology

1 reference

27 March 2018

volume

7

1 reference

27 March 2018

issue

3

1 reference

27 March 2018

page(s)

119-124

1 reference

27 March 2018

Quality of life end points in cancer clinical trials: review and recommendations

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

Impact of Event Scale: A Measure of Subjective Stress

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

Physiologic and psychobehavioral research in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

Psychoneuroimmunology. Implications for oncology?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

Psychoneuroimmunology and cancer: historical perspectives and current research

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2801%2900182-X

7 January 2021

10.1016/S1078-1439(01)00182-X

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018